Last updated: February 23, 2026
Market Analysis and Price Projections for NDC 49884-0155
Overview of NDC 49884-0155
NDC 49884-0155 corresponds to Rezlidhia (olutasidenib), a targeted therapy aimed at specific genetic mutations associated with certain hematological malignancies, notably acute myeloid leukemia (AML). It operates as an IDH1 inhibitor, authorized through a recent FDA accelerated approval pathway, reflecting its potential in precision oncology.
Current Market Landscape
Indications: Primarily approved for adult patients with AML harboring IDH1 mutations, resistant or refractory to initial therapy. The drug's approval follows an unmet need in this subset, driving interest among oncologists and hematologists.
Competitive Environment:
| Competitor drugs |
Mechanism |
Market share (est. 2023) |
Price range (per 30-day supply) |
| Ivosidenib (Tibsovo) |
IDH1 inhibitor |
65% |
$18,000 - $20,000 |
| Enasidenib (Idhifa) |
IDH2 inhibitor |
20% |
$19,000 - $21,000 |
| Rezlidhia (olutasidenib) |
IDH1 inhibitor |
10% |
Starting at $22,000 |
| Emerging therapies (e.g., venetoclax combos) |
BCL-2 inhibition and other pathways |
5% |
Varies |
Market Entry Factors:
- Limited competition due to the novel mechanism
- Early prescriber adoption driven by FDA approval for refractory cases
- High unmet clinical need sustains potential growth
Market Size and Demand Forecast
Incidence of AML with IDH1 mutations:
- Approximate annual cases in the US: 20,000.
- Estimated prevalence of IDH1 mutations in AML: 8-12%.
- Potential eligible patient pool: 1,600 to 2,400 annually.
Market penetration assumptions:
| Year |
Market Penetration |
Patient Population |
Units Sold (approx.) |
Revenue Estimate (USD) |
| 2023 |
10% |
160 patients |
1,920 units |
$42 million |
| 2024 |
15% |
240 patients |
2,880 units |
$63 million |
| 2025 |
25% |
400 patients |
4,800 units |
$105 million |
Note: Assumes median duration of therapy of approximately 6 months and stable pricing.
Price Projection
- Initial launch price: ~$22,000 per month.
- Price adjustments: May decrease as competition increases or through payer negotiations.
- Potential discounts: 10-15% with high-volume or institutional contracts.
Long-term scenario:
As more data becomes available and if approval expands to earlier lines or combination regimens, prices could stabilize or decline slightly. However, a premium could persist due to its targeted patient population.
Regulatory and Reimbursement Considerations
- FDA status: Accelerated approval; full approval contingent upon confirmatory trials.
- Payer dynamics: Likely to face negotiations for formulary placement; high cost could pressure utilization.
- Pricing strategies: Manufacturer may implement value-based pricing tied to clinical outcomes.
Risks and Opportunities
- Risks: Limited trial data, potential for pricing constraints, competition from emerging agents.
- Opportunities:
- Expand label to earlier lines of therapy.
- Combination therapy approvals with other agents.
- Development of companion diagnostics to identify eligible patients efficiently.
Key Takeaways
- NDC 49884-0155 (Rezlidhia) addresses a niche but high unmet need within AML with IDH1 mutations.
- Estimated U.S. market size: 1,600–2,400 eligible patients annually.
- First-year sales projection: approximately $42 million, potentially reaching $105 million by year three.
- Pricing estimated at around $22,000/month, subject to discounts and payer negotiation.
- Competitive landscape remains limited, but price and market share growth are contingent on clinical data and label expansion.
FAQs
Q1: How does Rezlidhia differ from existing IDH1 inhibitors?
A1: Rezlidhia has a distinct molecular structure and was approved based on specific clinical trial data demonstrating efficacy in refractory AML, potentially offering benefits in certain patient subsets.
Q2: What are the primary barriers to Rezlidhia's market growth?
A2: Limited clinical data outside the initial approval, payer negotiations, and the small pool of eligible patients constrain growth.
Q3: Could Rezlidhia’s price decline with increased competition?
A3: Yes. As more IDH1 inhibitors enter the market or combination therapies prove superior, prices may decrease due to competition.
Q4: What is the regulatory outlook for Rezlidhia?
A4: Full approval depends on ongoing confirmatory trials, with potential for label expansion if future data support broader indications.
Q5: How might new diagnostic tools impact Rezlidhia’s market?
A5: Improved companion diagnostics could increase eligible patient identification, expanding the market and facilitating targeted therapy deployment.
References
[1] FDA. (2022). FDA approves olutasidenib for myeloid malignancies.
[2] MarketWatch. (2023). Oncology drug market size and trends.
[3] IQVIA. (2023). Oncology R&D and sales data.
